Biogen Inc (fra:IDP) Share Price

Company Profile

Business description
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Contact
225 Binney Street
CambridgeMA02142
USA
T: +1 617 679-2000
E: [email protected]
https://www.biogen.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
7,500

Recommended

Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player

Nathan Zaia | 11 August 2026

Shares in Aussie listed healthcare name undervalued post earnings.

Lochlan Halloway, CFA | 11 August 2026

Wide moat share continues to grow despite a challenging residential construction market.

Esther Holloway | 10 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,404.70	0.80	-0.01%
CAC 40	8,709.51	5.43	-0.06%
DAX 40	26,508.89	117.47	0.45%
Dow JONES (US)	53,791.85	184.13	-0.34%
FTSE 100	10,848.80	4.61	0.04%
HKSE	25,440.17	212.65	-0.83%
NASDAQ	26,445.45	159.91	-0.60%
Nikkei 225	67,524.06	553.84	0.83%
NZX 50 Index	13,737.66	123.00	-0.89%
S&P 500	7,728.20	24.91	-0.32%
S&P/ASX 200	9,209.40	2.20	-0.02%
SSE Composite Index	3,946.68	12.58	0.32%